$16.54
1.04% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

ACADIA Pharmaceuticals Inc. Stock price

$16.54
+2.20 15.34% 1M
+1.34 8.82% 6M
-14.77 47.17% YTD
-5.58 25.23% 1Y
-3.24 16.38% 3Y
-31.22 65.37% 5Y
-12.99 43.99% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.17 1.04%
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

Key metrics

Market capitalization $2.75b
Enterprise Value $2.24b
P/E (TTM) P/E ratio 21.41
EV/FCF (TTM) EV/FCF 11.03
EV/Sales (TTM) EV/Sales 2.41
P/S ratio (TTM) P/S ratio 2.96
P/B ratio (TTM) P/B ratio 4.77
Revenue growth (TTM) Revenue growth 47.06%
Revenue (TTM) Revenue $929.24m
EBIT (operating result TTM) EBIT $112.24m
Free Cash Flow (TTM) Free Cash Flow $202.66m
Cash position $565.33m
EPS (TTM) EPS $0.77
P/E forward 22.74
P/S forward 2.83
EV/Sales forward 2.30
Short interest 7.74%
Show more

Is ACADIA Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

13x Buy
65%
6x Hold
30%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy
65%
Hold
30%
Sell
5%

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
929 929
47% 47%
100%
- Direct Costs 78 78
198% 198%
8%
851 851
41% 41%
92%
- Selling and Administrative Expenses 458 458
16% 16%
49%
- Research and Development Expense 269 269
25% 25%
29%
125 125
183% 183%
13%
- Depreciation and Amortization 12 12
177% 177%
1%
EBIT (Operating Income) EBIT 112 112
173% 173%
12%
Net Profit 129 129
186% 186%
14%

In millions USD.

Don't miss a Thing! We will send you all news about ACADIA Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACADIA Pharmaceuticals Inc. Stock News

Neutral
Business Wire
5 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gable...
Neutral
Business Wire
11 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units (“RSUs”) to twenty-three new employees under Acadia's 2024 Induc...
Positive
Seeking Alpha
15 days ago
Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth.
More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office United States
CEO Catherine Owen
Employees 598
Founded 1993
Website www.acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today